INAB - In8bio Inc
In8bio Inc Logo

INAB - In8bio Inc

https://in8bio.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers, including solid tumors using genetically modified, autologous, allogeneic gamma-delta T cells. The company is headquartered in New York, New York.

52W High
$16.71
52W Low
$1.98
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.02
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-1.15
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
0.65
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
5.56%
Institutions (25–75% balanced)
19.29%
Shares Outstanding
4,539,700
Float
4,179,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-9.16
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-1.66%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
-0.0764
Previous
-0.0805
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025